Simon N.r. Harford - 27 Apr 2026 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Reporting relationship: Chief Financial Officer
Issuer ticker: FOLD
Reported as of: 27 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Apr 2026, 16:37:52 UTC
Prior SEC filing: 30 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Christian Formica, Attorney-in-Fact

Key filing fact

Simon N.r. Harford filed Form 4 for AMICUS THERAPEUTICS, INC. (FOLD) on 27 Apr 2026.

Key facts

This page summarizes Simon N.r. Harford's Form 4 filing for AMICUS THERAPEUTICS, INC. (FOLD).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 27 Apr 2026, 16:37.

Change

Previous filing in this sequence was filed on 30 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001443705 Primary reporting owner

Harford Simon N.R.

Relationship: Chief Financial Officer
Address: 47 HULFISH STREET, PRINCETON
Signature: /s/ Christian Formica, Attorney-in-Fact
Signature date: 27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FOLD transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -143,595
Change %: -100%
Price: $14.50^*
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -189,043
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 189,043
Exercise price: $12.62
Footnotes: F2, F3

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -99,073
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 99,073
Exercise price: $14.24
Footnotes: F2, F3

FOLD transaction Derivative

Stock Options (right to buy)

Disposed to Issuer

Transaction value
Shares: -150,517
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,517
Exercise price: $9.41
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Simon N.r. Harford is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 108,478 shares of Common Stock and 35,117 restricted stock units (which vested in full in connection with consummation of the Merger).

Footnote F2

In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

Footnote F3

Each Option vested in full in connection with consummation of the Merger.